UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                   FORM 10-QSB
(Mark One)

[X]  QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
     ACT OF 1934

For the quarterly period ended    March 31, 2004
                               ------------------------

[]   TRANSITION  REPORT  PURSUANT  TO  SECTION  13 OR  15(d)  OF THE  SECURITIES
     EXCHANGE ACT OF 1934

For the transition period from ________________ to _______________

Commission File No.     33-55254-09

                        Rocky Point Pharmaceuticals, Inc.
        (Exact name of Small Business Issuer as specified in its charter)

         NEVADA                              87-0434293
------------------------------------    --------------------------
(State or other jurisdiction of         (I.R.S. Employer
incorporation or organization)          Identification Number)

9350 South 150 East, Suite 900
         Sandy, Utah                                          84070
------------------------------------                 ------------------
(Address of principal executive offices)             (Zip Code)

Issuer's telephone number, including area code     (801) 617-2040
                                               ------------------------------

         Indicate by check mark whether the Issuer (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the Issuer
was required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days. [X] Yes [ ] No

         Indicate the number of shares outstanding of each of the Issuer's
classes of common stock, as of the latest practicable date.

             Class                            Outstanding as of April 9, 2004
------------------------------------         --------------------------------
$.001 PAR VALUE CLASS A COMMON STOCK                 13,069,000 SHARES

                                        1

<PAGE>



                         PART 1 - FINANCIAL INFORMATION

Item 1.  Financial Statements.

BASIS OF REPRESENTATION

General

         The accompanying unaudited financial statements have been prepared in
accordance with the instructions to Form 10-QSB and, therefore, do not include
all information and footnotes necessary for a complete presentation of financial
position, results of operations, cash flows and stockholders' (deficit) in
conformity with generally accepted accounting principles. In the opinion of
management, all adjustments considered necessary for a fair presentation of the
results of operations and financial position have been included and all such
adjustments are of a normal recurring nature. Operating results for the nine
months ended March 31, 2004, are not necessarily indicative of the results that
can be expected for the year ending June 30, 2004.


                                        2

<PAGE>



                        Rocky Point Pharmaceuticals, Inc.
                          (A Development Stage Company)
                                 BALANCE SHEETS


<TABLE>
<CAPTION>
                                                                                  March 31,
                                                                                    2004
                                                                                 (Unaudited)
                                                                           ----------------------
ASSETS
   CURRENT ASSETS
<S>                                                                        <C>
     Cash in bank                                                          $                    0
     Accounts receivable                                                                       69
                                                                           ----------------------

                                                   TOTAL CURRENT ASSETS    $                   69
                                                                           ======================

LIABILITIES & (DEFICIT)
   CURRENT LIABILITIES
     Accounts payable                                                      $                    0
     Payable - related parties (Note 4)                                                     4,901
                                                                           ----------------------

                                              TOTAL CURRENT LIABILITIES                     4,901

   STOCKHOLDERS' EQUITY (DEFICIT)
    Common Stock $.001 par value:
       Authorized - 100,000,000 shares
       Issued and outstanding 13,069,000
         and 13,000,000 shares, respectively                                               13,069
     Deficit accumulated during the
       development stage                                                                  (17,901)
                                                                           ----------------------

         TOTAL STOCKHOLDERS' EQUITY (DEFICIT)                                              (4,832)
                                                                           ----------------------

                                                                           $                   69
                                                                           ======================
</TABLE>


                       See Notes to Financial Statements.

                                        3

<PAGE>



                        Rocky Point Pharmaceuticals, Inc.
                          (A Development Stage Company)
                            STATEMENTS OF OPERATIONS
                                   (Unaudited)




<TABLE>
<CAPTION>
                                                                                                                     4/14/1986
                                           Three Months Ended                       Nine Months Ended                (Date of
                                                March 31,                               March 31,                  inception) to
                                        2004                2003                2004               2003           March 31, 2004
                                 ------------------  ------------------  -----------------   -----------------  ------------------
<S>                              <C>                 <C>                 <C>                 <C>                <C>
Net sales                        $                0  $                0  $               0   $               0  $                0
Cost of sales                                     0                   0                  0                   0                   0
                                 ------------------  ------------------  -----------------   -----------------  ------------------

                   GROSS PROFIT                   0                   0                  0                   0                   0

General and administrative
   expenses                                   3,200                 600              3,200               2,800              18,701
                                 ------------------  ------------------  -----------------   -----------------  ------------------

Other Income
   Gain on Sale of Subsidiary                     0                 800                  0                 800                 800
                                 ------------------  ------------------  -----------------   -----------------  ------------------

              NET INCOME (LOSS)  $           (3,200) $              200  $          (3,200)  $          (2,000) $          (17,901)
                                 ==================  ==================  =================   =================  ==================

Basic and Diluted
   earnings per share
     Net income (loss) per
       weighted average share    $             (.00) $              .00  $            (.00)  $            (.00)
                                 ==================  ==================  =================   =================

Weighted average number
   of common shares used to
   compute net income (loss)
   per weighted average share            13,069,000          13,000,000         13,069,000          13,000,000
                                 ==================  ==================  =================   =================
</TABLE>



                       See Notes to Financial Statements.

                                        4

<PAGE>



                        Rocky Point Pharmaceuticals, Inc.
                          (A Development Stage Company)
                            STATEMENTS OF CASH FLOWS
                                   (Unaudited)

<TABLE>
<CAPTION>
                                                                                                                      4/14/1986
                                               Three Months Ended                     Nine Months Ended               (Date of
                                                    March 31,                             March 31,                 inception) to
                                              2004               2003              2004                2003           3/31/2004
                                        ---------------     ---------------  ----------------    ---------------   ---------------
OPERATING ACTIVITIES
<S>                                     <C>                 <C>              <C>                 <C>               <C>
   Net income (loss)                    $        (3,200)    $          (200) $         (3,200)   $        (2,000)  $       (17,901)
   Adjustments to reconcile net income
     (loss) to cash used by operating
     activities:
       Amortization                                   0                   0                 0                  0                50
       Stock issued for expenses                      0                   0                 0                  0            12,000
       Changes in accounts payable                    0              (1,400)             (900)            (2,500)                0
       Changes in accounts receivable                 0                   0               (69)                 0               (69)
       Changes in prepaid expenses                2,000                   0                 0                  0                 0
       Payable - related parties                  1,200            (100,049)            4,100           (105,249)            4,901
                                        ---------------     ---------------  ----------------    ---------------   ---------------

                      NET CASH USED BY
                  OPERATING ACTIVITIES                0            (101,249)              (69)          (109,749)           (1,019)
                                        ---------------     ---------------  ----------------    ---------------   ---------------

INVESTING ACTIVITIES
   Organization Costs                                 0                   0                 0                  0               (50)
   Sale of subsidiary                                 0             100,050                 0            109,749                 0
                                        ---------------     ---------------  ----------------    ---------------   ---------------

                  NET CASH PROVIDED BY
                  INVESTING ACTIVITIES                0             100,050                 0            109,749               (50)
                                        ---------------     ---------------  ----------------    ---------------   ---------------

FINANCING ACTIVITIES
   Issuance of common stock                           0                   0               (69)                 0             1,069
                                        ---------------     ---------------  ----------------    ---------------   ---------------

                      NET CASH USED BY
                  FINANCING ACTIVITIES                0                   0                69                  0             1,069

                   INCREASE (DECREASE)
                             IN CASH &
                      CASH EQUIVALENTS                0              (1,199)                0                  0                 0

Cash and cash equivalents at
   beginning of period                                0               1,199                 0                  0                 0
                                        ---------------     ---------------  ----------------    ---------------   ---------------

               CASH & CASH EQUIVALENTS
                      AT END OF PERIOD  $             0     $             0  $              0    $             0   $             0
                                        ===============     ===============  ================    ===============   ===============
</TABLE>




                       See Notes to Financial Statements.

                                        5

<PAGE>



                        Rocky Point Pharmaceuticals, Inc.
                          (A Development Stage Company)
                          NOTES TO FINANCIAL STATEMENTS
                                 March 31, 2004


NOTE 1:       CHANGE IN REPORTING ENTITY

              The statement of operations reflects the acquisition of Rocky
              Point Pharmaceuticals, Inc. ("Rocky Point") a reporting company
              under the Securities Act of 1934, by Luong Dae Solutions,
              Inc.,("Luong Dae") a development-stage company, on June 26, 2002
              in a reverse acquisition, consummated by issuing 11,000,000 shares
              of common stock of Rocky Point to the founders of Luong Dae.
              Reverse acquisition accounting is appropriate since the
              shareholders of Luong Dae controlled approximately 92% of the
              outstanding common stock of Rocky Point immediately after the
              acquisition, and management of Luong Dae controlled the board of
              directors and day-to-day management of the Company after the
              acquisition. The reverse acquisition constitutes a change in
              reporting entity for accounting purposes. This reverse acquisition
              is considered to be a capital transaction (i.e. issuance of stock
              by Rocky Point accompanied by a recapitalization). The historical
              financial statements reflect the assets and liabilities of Luong
              Dae at their historical cost. Rocky Point had no assets on the
              date of the reverse acquisition. Rocky Point had liabilities of
              $7,550 on the date of the reverse acquisition.

              At March 31, 2003, the Company sold its interest in Loung Dae.
              Previous financial statements of the Company captioned
              "Consolidated Financial Statements" presented the financial
              condition of the Company together with that of Luong Dae, then a
              majority-owned subsidiary of the Company, on a consolidated basis.
              The disposal of the Company's interest in Luong Dae, which had no
              material net assets or liabilities, had no direct actual impact on
              the financial condition resulting from the de-consolidation of
              Luong Dae.

NOTE 2:       SUMMARY OF SIGNIFICANT ACCOUNTING PRINCIPLES

              Accounting Methods:
              The Company recognizes income and expenses based on the accrual
              method of accounting.

              Dividend Policy:
              The Company has not yet adopted any policy regarding payment of
              dividends.

              Cash and Cash Equivalents:
              For financial statement purposes, the Company considers all highly
              liquid investments with an original maturity date of three months
              or less when purchased to be cash equivalents.

              Estimates:
              The preparation of financial statements in conformity with
              generally accepted accounting principles requires management to
              make estimates and assumptions that affect the reported amounts of
              assets, liabilities, revenues and expenses during the reporting
              period. Estimates also affect the disclosure of contingent assets
              and liabilities at the date of the financial statements. Actual
              results could differ from these statements.

              Net Loss Per Share:
              Basic and diluted loss per share is computed by dividing net loss
              available to common shareholders by the weighted average number of
              common shares outstanding during the periods presented.

              Income Taxes:
              The Company utilizes the liability method of accounting for income
              taxes as set forth in Statement of Financial Accounting Standards
              No. 109, "Accounting for Income Taxes" (SFAS 109). Under the
              liability method, deferred taxes are determined based on the
              difference between the financial statement and tax bases of assets
              and liabilities using enacted tax rates in effect in the years in
              which the differences are expected to reverse. An allowance
              against deferred tax assets is recorded when it is more likely
              than not that such tax benefits will not be realized.

                                        6

<PAGE>



                        Rocky Point Pharmaceuticals, Inc.
                          (A Development Stage Company)
                    NOTES TO FINANCIAL STATEMENTS (continued)
                                 March 31, 2004



NOTE 2:       SUMMARY OF SIGNIFICANT ACCOUNTING PRINCIPLES

              At June 30, 2003 a deferred tax asset of about $4,700 has been
              fully reserved due to the Company's lack of operations to provide
              income to use the net operating loss carryover of $13,900 which
              expires as follows:

               Year Ended           Expires            Amount
              -------------      -------------       ----------------
              June 30, 2002      June 30, 2022       $         11,000
              June 30. 2003      June 30, 2023                  2,900
                                                     ----------------
                                                     $         13,900
                                                     ================

NOTE 3:       DEVELOPMENT STAGE COMPANY
              The Company was originally incorporated as Upsilon, Inc. under the
              laws of the State of Utah on April 14, 1986 and has been in the
              development stage since incorporation. On December 30, 1993, the
              Company was dissolved as a Utah corporation and reincorporated in
              Nevada as Upsilon Industries, Inc. On July 21, 1995, the Company
              changed its name to TTN Capitol, Inc., on October 15, 1995, the
              Company changed its name to Wasatch Pharmaceutical, Inc., and on
              May 31, 2000 the Company changed its name to Rocky Point
              Pharmaceuticals, Inc. Luong Dae was incorporated on April 14, 1986
              in Nevada, and became a subsidiary of the Company on June 26,
              2002. Luong Dae was disposed of on March 31, 2003.

NOTE 4:       RELATED PARTY TRANSACTIONS
              The Company neither owns nor leases any real property. Office
              services are provided, without charge, by an officer. Such costs
              are immaterial to the financial statements, and, accordingly, have
              not been reflected therein. The officers and directors of the
              Company are involved in other business activities and may, in the
              future, become involved in other business opportunities. If a
              specific business opportunity becomes available, such persons may
              face a conflict in selecting between the Company and their other
              business interests. The Company has not formulated a policy for
              the resolution of such conflicts. At March 31, 2004 the Company
              owes $4,901 to a shareholder for expenses paid on behalf of the
              Company.

NOTE 5:       COMMON STOCK
              On July 22, 2003, 69,000 shares of Regulation S stock was issued
              at par. The Company recorded a receivable of $69 on that date.

NOTE 6:       GOING CONCERN ITEMS
              The financial statements are presented on the basis that the
              Company is a going concern, which contemplates the realization of
              assets and the satisfaction of liabilities in the normal course of
              business over a reasonable length of time. At March 31, 2004, the
              Company has no material assets and all its expenses are being paid
              by its CEO. The Company has a substantial need for working
              capital.

              Management feels that loans from related parties and issuance of
              stock will provide sufficient working capital to allow the Company
              to continue as a going concern.

                                        7

<PAGE>



Item 2.  Management's Discussion and Analysis of Financial Condition and Results
         of Operations

         The Company has had no operational history and has yet to engage in
business of any kind. All risks inherent in new and inexperienced enterprises
are inherent in the Company's business. The Company has not made a formal study
of the economic potential of any business. At the present, the Company has not
identified any assets or business opportunities for acquisition. The only
activity for the period ended March 31, 2004 was the incurrence of costs
associated with periodic filings of required forms with the SEC.

         The Company has no liquidity and no presently available capital
resources, such as credit lines, guarantees, etc. and should a merger or
acquisition prove unsuccessful, it is possible that the Company may be dissolved
by the State of Nevada for failing to file reports. Should management decide not
to further pursue its acquisition activities, management may abandon its
activities and the shares of the Company would become worthless.

         Based on current economic and regulatory conditions, Management
believes that it is possible, if not probable, for a company like the Company,
without many assets or liabilities, to negotiate a merger or acquisition with a
viable private company. The opportunity arises principally because of the high
legal and accounting fees and the length of time associated with the
registration process of "going public". However, should any of these conditions
change, it is very possible that there would be little or no economic value for
anyone taking over control of the Company.

                           PART II - OTHER INFORMATION

Item 6.    Exhibits and Reports on Form 8-K

           (a)  Exhibits
                Exhibit 31 CEO Certification
                Exhibit 32 CFO Certification

           (b)  Reports on Form 8-K None.

                                   SIGNATURES

         Pursuant to the requirements of the Securities and Exchange Act of
1934, the Issuer has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.

                        Rocky Point Pharmaceuticals, Inc.


Dated: April 2, 2004         By:  /s/ Mark Timothy
      ---------------           -----------------------------------------
                             Mark Timothy, Acting President and Director

         Pursuant to the requirements of the Securities Exchange Act of 1934,
this report has been signed below by the following persons on behalf of the
registrant and in the capacities and on the dates indicated.


Dated: April 2, 2004         By:  /s/ Mark Timothy
       -------------            -----------------------------------------
                             Mark Timothy, Acting President and Director


                                        8

<PAGE>



Exhibit 31
                                 Certifications

I, Mark Timothy certify that:

     1.  I have reviewed this quarterly report on Form 10-QSB of Rocky Point
         Pharmaceuticals, Inc.;

     2.  Based on my knowledge, this quarterly report does not contain any
         untrue statements of a material fact or omit to state a material fact
         necessary to make the statements made, in light of the circumstances
         under which such statements were made, not misleading with respect to
         the period covered by this quarterly report;

     3.  Based on my knowledge, the financial statements, and other financial
         information included in this quarterly report, fairly present in all
         material respects the financial condition, results of operations, and
         cash flows of the registrant as of, and for, the periods presented in
         this quarterly report;

     4.  I am responsible for establishing and maintaining disclosure controls
         and procedures (as defined in Exchange Act Rules 13a-15(e) and
         15d-15(e)) for the registrant and have:

         a.   Designed such disclosure controls and procedures to ensure that
              material information relating to the registrant particularly
              during the period in which this quarterly report is being
              prepared;

         b.   Evaluated the effectiveness of the registrant's disclosure
              controls and procedures and presented in this report our
              conclusions about the effectiveness of the disclosure controls and
              procedures, as of the end of the period covered by this report
              based on such evaluations; and

         c.   Disclosed in this report any changes in the registrant's internal
              control over financial reporting that occurred during the
              registrant's most recent fiscal quarter (the registrant's fourth
              fiscal quarter in the case of an annual report) that has
              materially affected, or is reasonably likely to materially affect,
              the registrant's internal control over financial reporting; and

     5.  I have disclosed, based on my most recent evaluation, to the
         registrant's auditors and registrant's board of directors (or persons
         performing the equivalent functions):

         a.   All significant deficiencies and material weaknesses in the design
              or operation of internal control over financial reporting which
              are reasonably likely to adversely affect the registrant's ability
              to record, process, summarize and report financial information;
              and

         b.   Any fraud, whether or not material, that involves management or
              other employees who have a significant role in the registrant's
              internal control over financial reporting.


Date:  April 2, 2004
      --------------------------------------

/s/ Mark Timothy
Mark Timothy, President,
CEO, CFO, and Director


                                        9

<PAGE>


Exhibit 32

                    CERTIFICATION OF CHIEF FINANCIAL OFFICER
                                   PURSUANT TO
                             18 U.S.C. SECTION 1350,
                             AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002


I, Mark Timothy, certify, pursuant to 18 U.S.C. Section 1350, as adopted
pursuant to Section 906 of the Sarbanes- Oxley Act of 2002, that the Quarterly
Report on Form 10QSB of Rocky Point Pharmaceuticals, Inc. for the quarterly
period ending March 31, 2004 fully complies with the requirements of Section
13(a) or 15(d) of the Securities Exchange Act of 1934 and that the information
contained in the Quarterly Report on Form 10QSB fairly presents in all material
respects the financial condition and results of operations of Rocky Point
Pharmaceuticals, Inc.


                                       By:
Date: April 2, 2004                    /s/ Mark Timothy
     ----------------------             -------------------------
                                        Mark Timothy
                                        Chief Financial Officer


                                       10